ストックスクリーナーアプリを入手
7.09
4.32%
-0.32
プレマーケット:
7.51
0.42
+5.92%
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates - Kalkine
Karyopharm Therapeutics Inc (KPTI) Cash Flow - TradingKey
Karyopharm Therapeutics Inc (KPTI) Balance Sheet - TradingKey
KPTI|Karyopharm Therapeutics Inc|Price:7.410|Chg%:+0.320 - TradingKey
Karyopharm Therapeutics Inc (KPTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KPTI|Karyopharm Therapeutics Inc|Price:7.605|Chg%:+0.195 - TradingKey
Karyopharm Therapeutics Inc (KPTI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Karyopharm Therapeutics Inc (KPTI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Karyopharm stock trades lower after revenue declines and cash burn widens - Ad-hoc-news.de
KPTI Q2'26 Earnings: revenue estimate is 33.12M USD - TradingView
Karyopharm Therapeutics Inc (KPTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Karyopharm: 'Hold' Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI) - Seeking Alpha
RBC Capital reiterates Karyopharm stock rating on compensation plan By Investing.com - Investing.com Canada
Karyopharm drops 21% following disclosure of executive cash retention plan - MSN
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI) - Seeking Alpha
Karyopharm Pharmaceuticals (KPTI) Sees 21% Drop Amid Leadership Cash Retention Program - GuruFocus
KPTI Shares Drop Significantly After Compensation Plan Update - GuruFocus
Karyopharm Therapeutics (KPTI) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Stocks to Wtach: Karyopharm Therapeutics, MKDWELL, Advanced Biomed - Moomoo
Karyopharm Therapeutics Slides on Disclosure of Cash-Retention Program for Executives - Moomoo
Karyopharm Therapeutics Launches 2026 Leadership Cash Retention Program for Key Executives - Minichart
Karyopharm Launches 2026 Executive Retention Incentive Program - TipRanks
Karyopharm Therapeutics (NASDAQ: KPTI) grants 2026 cash retention awards to key executives - Stock Titan
KPTI5813817 Bond Coupon Profile — Rate & Payments - TradingView
KPTI5813817 Bond Risk Profile - TradingView
KPTI5813817 Bond Profile — Key Metrics - TradingView
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm stock trades steadily as investors watch Selinexor franchise - AD HOC NEWS
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Karyopharm Therapeutics faces a data setback as investors weigh late-stage cancer pipeline - Ad Hoc News
KPTIKaryopharm Therapeutics Inc Latest SEC Filings - Finviz
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm gives 4 new hires stock awards vesting over 3 years - Stock Titan
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Value Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2500 Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000E Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2500 Index - marketscreener.com
Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Price to sales forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000 Index - marketscreener.com
Price to earnings forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Enterprise value to revenue forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $KPTI - MarketBeat
Karyopharm Therapeutics, Inc. Actuals & Estimates (NASDAQ:KPTI) - TradingView
25K0 Forecast — Price Target — Prediction for 2027 - TradingView
KPTI Forecast — Price Target — Prediction for 2027 - TradingView
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Yahoo Finance
Dyne Therapeutics Appoints Barry Greene to Board of Directors - GlobeNewswire
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell - Seeking Alpha
Karyopharm Therapeutics Inc (KPTI) Valuation: PE, PB & Fair Value Analysis - TradingKey
H.C. Wainwright reiterates Karyopharm stock rating on trial data By Investing.com - Investing.com Canada
Karyopharm Therapeutics Inc (KPTI) Institutional Confidence - TradingKey
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):